Immunotargeting and Radiobiology in Oncology : A. Pèlegrin


Our research is organized around 3 closely related research themes

  • Human Epidermal Receptor (HER) family: from combinations of approved monoclonal antibodies (mAbs) to original mAbs against receptors and ligands, and back
  • MISR-II: the original ovarian carcinoma target
  • Severe late adverse effects after radiotherapy: analysis of the causes and design of a predictive assay


Research Summary

Our research focuses on the treatment of solid tumors by using antibodies and radiotherapy with a special attention to drug-induced resistance. To this aim, we design, develop and evaluate monoclonal antibodies (mAbs) to target antigens the expression of which is enhanced when tumors become resistant to a treatment and we combine them to identify synthetic lethal interactions for anti-cancer drug discovery/improvement.


Our main objectives are: (i) to design and develop new antibodies and derived molecules; (ii) to improve the efficacy of these targeted therapeutic approaches; and (iii) to understand the underlying mechanisms of action.

Lire la suite


Talbot C, Veldwijk M, Azria D, Batini C, Bierbaum M, Brengues M, Chang-Claude J, Johnson K, Keller A, Smith S, Sperk E, Symonds R, Wenz F, West C, Herskind C Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Clin Transl Radiat Oncol. 2019;18. doi:10.1016/j.ctro.2019.06.001

Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int. J. Cancer. Mar 18, 2019. doi:10.1002/ijc.32273

Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023

Boogerd L, Hoogstins C, Schaap D, Kusters M, Handgraaf H, van der Valk M, Hilling D, Holman F, Peeters K, Mieog J, van de Velde C, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs S, de Hingh I, Nieuwenhuijzen G, Rutten H, Burggraaf J, Vahrmeijer A Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181-191. doi:10.1016/S2468-1253(17)30395-3

Leconet W, Chentouf M, Chevalier C, Sirevnt A, Ait-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J, Pelegrin A, Larbouret C, Robert B Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis. Clin Cancer Res. 2017;23. doi:10.1158/1078-0432.CCR-16-1316


Responsable : André Pèlegrin

Institut de Recherche en
Cancérologie de Montpellier
CRLC Val d’Aurelle-Paul Lamarque
34298 Montpellier cedex 5

Tél. : 33 (0)4 67 61 30 32
Fax : 33 (0)4 67 61 37 87



Partners and Funding




© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés